1497 related articles for article (PubMed ID: 8233650)
1. [Expression of P53 protein in cutaneous melanoma].
Casazza S; Gambini C; Tunesi G; Rovida S; Caruso F; Pastorino A; Canepa M
Pathologica; 1993; 85(1097):335-42. PubMed ID: 8233650
[TBL] [Abstract][Full Text] [Related]
2. Prognostic prediction of the immunohistochemical expression of p16 and p53 in cutaneous melanoma: a comparison of two populations from different geographical regions.
Sirigu P; Piras F; Minerba L; Murtas D; Maxia C; Colombari R; Corbu A; Perra MT; Ugalde J
Eur J Histochem; 2006; 50(3):191-8. PubMed ID: 16920642
[TBL] [Abstract][Full Text] [Related]
3. Flow cytometric analysis of p53 oncoprotein expression in cutaneous melanoma.
Ross DA; Wilson GD
Br J Surg; 1997 Jun; 84(6):803-7. PubMed ID: 9189093
[TBL] [Abstract][Full Text] [Related]
4. The developmentally regulated neural crest-associated glycotope HNK-1 predicts metastasis in cutaneous malignant melanoma.
Thies A; Schachner M; Berger J; Moll I; Schulze HJ; Brunner G; Schumacher U
J Pathol; 2004 Aug; 203(4):933-9. PubMed ID: 15258996
[TBL] [Abstract][Full Text] [Related]
5. p53 expression in cutaneous malignant melanoma: an immunohistochemical study of 87 cases of primary, recurrent, and metastatic melanoma.
Barnhill RL; Castresana JS; Rubio MP; Martin MT; Idoate M; Vazquez JJ; Thor AD
Mod Pathol; 1994 Jun; 7(5):533-5. PubMed ID: 7937717
[TBL] [Abstract][Full Text] [Related]
6. PUMA expression is significantly reduced in human cutaneous melanomas.
Karst AM; Dai DL; Martinka M; Li G
Oncogene; 2005 Feb; 24(6):1111-6. PubMed ID: 15690057
[TBL] [Abstract][Full Text] [Related]
7. p21(WAF1/CIP1) expression in stage I cutaneous malignant melanoma: its relationship with p53, cell proliferation and survival.
Karjalainen JM; Eskelinen MJ; Kellokoski JK; Reinikainen M; Alhava EM; Kosma VM
Br J Cancer; 1999 Feb; 79(5-6):895-902. PubMed ID: 10070887
[TBL] [Abstract][Full Text] [Related]
8. Proteins involved in pRb and p53 pathways are differentially expressed in thin and thick superficial spreading melanomas.
de Sá BC; Fugimori ML; Ribeiro Kde C; Duprat Neto JP; Neves RI; Landman G
Melanoma Res; 2009 Jun; 19(3):135-41. PubMed ID: 19369901
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of cell cycle modulators p21, p27, p53, Rb and proapoptotic Bcl-2-related proteins Bax and Bak in cutaneous melanoma is associated with worse patient prognosis: preliminary findings.
Tchernev G; Orfanos CE
J Cutan Pathol; 2007 Mar; 34(3):247-56. PubMed ID: 17302609
[TBL] [Abstract][Full Text] [Related]
10. p53 Protein expression in nevi and melanomas.
Cristofolini M; Boi S; Girlando S; Zumiani G; Cristofolini P; Dalla Palma P; Doglioni C; Barbareschi M
Arch Dermatol; 1993 Jun; 129(6):739-43. PubMed ID: 8507076
[TBL] [Abstract][Full Text] [Related]
11. Dermatopathological indicators of poor melanoma prognosis are significantly inversely correlated with the expression of NM23 protein in primary cutaneous melanoma.
Ferrari D; Lombardi M; Ricci R; Michiara M; Santini M; De Panfilis G
J Cutan Pathol; 2007 Sep; 34(9):705-12. PubMed ID: 17696918
[TBL] [Abstract][Full Text] [Related]
12. Skp2 and p27kip1 expression in melanocytic nevi and melanoma: an inverse relationship.
Li Q; Murphy M; Ross J; Sheehan C; Carlson JA
J Cutan Pathol; 2004 Nov; 31(10):633-42. PubMed ID: 15491322
[TBL] [Abstract][Full Text] [Related]
13. Reduced expression of p16 and p27 is correlated with tumour progression in cutaneous melanoma.
Sanki A; Li W; Colman M; Karim RZ; Thompson JF; Scolyer RA
Pathology; 2007 Dec; 39(6):551-7. PubMed ID: 18027257
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical expression of p53 protein, mitotic index and nuclear morphometry in primary malignant melanoma of the skin.
Talve L; Kainu J; Collan Y; Ekfors T
Pathol Res Pract; 1996 Aug; 192(8):825-33. PubMed ID: 8897518
[TBL] [Abstract][Full Text] [Related]
15. Expression of mutant p53 in melanoma.
Stretch JR; Gatter KC; Ralfkiaer E; Lane DP; Harris AL
Cancer Res; 1991 Nov; 51(21):5976-9. PubMed ID: 1933861
[TBL] [Abstract][Full Text] [Related]
16. Concurrent Ki-67 and p53 immunolabeling in cutaneous melanocytic neoplasms: an adjunct for recognition of the vertical growth phase in malignant melanomas?
Kaleem Z; Lind AC; Humphrey PA; Sueper RH; Swanson PE; Ritter JH; Wick MR
Mod Pathol; 2000 Mar; 13(3):217-22. PubMed ID: 10757331
[TBL] [Abstract][Full Text] [Related]
17. Expression of c-myc oncoprotein represents a new prognostic marker in cutaneous melanoma.
Ross DA; Wilson GD
Br J Surg; 1998 Jan; 85(1):46-51. PubMed ID: 9462382
[TBL] [Abstract][Full Text] [Related]
18. Measurement of c-myc oncogene expression provides an accurate prognostic marker for acral lentiginous melanoma.
Grover R; Chana J; Grobbelaar AO; Hudson DA; Forder M; Wilson GD; Sanders R
Br J Plast Surg; 1999 Mar; 52(2):122-6. PubMed ID: 10434891
[TBL] [Abstract][Full Text] [Related]
19. Analysis of p53 in human cutaneous melanoma cell lines.
Montano X; Shamsher M; Whitehead P; Dawson K; Newton J
Oncogene; 1994 May; 9(5):1455-9. PubMed ID: 8152807
[TBL] [Abstract][Full Text] [Related]
20. Primary melanoma of the skin and cutaneous melanomatous metastases: comparative histologic features and immunophenotypes.
Guerriere-Kovach PM; Hunt EL; Patterson JW; Glembocki DJ; English JC; Wick MR
Am J Clin Pathol; 2004 Jul; 122(1):70-7. PubMed ID: 15272532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
